Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage

Parkinsonism and Related Disorders

Volumn 18, Issue 5, 2012, Pages 686-687

  Munro Neville, A ^a   Parsons, Richard W ^a   Askmark, Håkan ^b   Nyholm, Dag ^b  

^a Pretium Pty Ltd   (Australia)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Hoehn Yahr scale; Levodopa carbidopa intestinal gel infusion; Meta analysis; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG USE; GEL; HOEHN AND YAHR STAGE; HUMAN; LETTER; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM;

ANTIPARKINSON AGENTS; CARBIDOPA; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; GELS; HUMANS; LEVODOPA; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84861194126     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.11.026     Document Type: Letter

References (5)

1. Nyholm D., Askmark H., Gomes-Trolin C., Knutson T., Lennernäs H., Nyström C., et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003, 26(3):156-163.
2. Nyholm D., Remahl A.I., Dizdar N., Constantinescu R., Holmberg B., Jansson R., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005, 64(2):216-223.
3. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17(5):427-442.
4. Antonini A., Isaias I.U., Canesi M., Zibetti M., Maneini F., Manfredi L., et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Movement Disorders 2007, 22(8):1145-1149.
5. Odin. Kongressreport. 5th German Parkinson's Congress. Besserung von motorischen und nicht-motorischen Symptomen. Neurologie & Rehabilitation, 2007; 2:119.